William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a clinical-stage ...

Healthcare Analysts, along with argenx ( ARGX) SE CEO Tim Van Hauwermeiren and Dr. Chafic Karam discuss Vyvgart on an Analyst/Industry conference call to be held on April 8 at 1 pm. Published first on ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Skye Bioscience (SKYE – Research Report). The company’s ...

William Blair analyst J. Schmitt now expects that the financial services provider will post earnings per share of $9.41 for the quarter, down from their previous forecast of $9.63.

William Blair also issued estimates for Ameriprise Financial’s Q2 2025 earnings at $9.10 EPS, FY2025 earnings at $37.60 EPS and FY2026 earnings at $41.50 EPS. Get Ameriprise Financial alerts: ...